Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

NCT01838499 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01838499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01838499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2013
Completion date
October 31, 2014
Enrollment
224 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa